Targeting MARylation and DePARylation in Cancer Therapy: New Promising Therapeutic Opportunities
Vanesa Cabeza-Fernández, Francisco Javier Ríos-Sola, David Martín-Oliva, Jerónimo Borrego-Pérez, Francisco Javier Oliver, José YéLamos, José Manuel Rodríguez-Vargas, Dik C van Gent · 2025
Read Targeting MARylation and DePARylation in Cancer Therapy: New Promising Therapeutic Opportunities by Vanesa Cabeza-Fernández, Francisco Javier Ríos-Sola, David Martín-Oliva, Jerónimo Borrego-Pérez, Francisco Javier Oliver, José YéLamos, José Manuel Rodríguez-Vargas, Dik C van Gent (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12731758.txt.
Description
Vanesa Cabeza-Fernández and co-authors review new drug targets in a family of enzymes that tag proteins with a sugar based mark. Their paper from 2025 deals with PARP enzymes, which keep cells in balance and play a role in many diseases. Most past work centered on the members tied to DNA repair.
A smaller subset of the family, which adds a single mark rather than a chain, has drawn growing notice in the last decade. These members guide cell growth, early development, and disease paths. The cycle of adding and removing the mark must stay in fine balance. The review weighs drugs that block the adders or the removers as cancer care, and the hard parts of making them act on one target only.
Catalog record
| CREATOR | Vanesa Cabeza-Fernández, Francisco Javier Ríos-Sola, David Martín-Oliva, Jerónimo Borrego-Pérez, Francisco Javier Oliver, José YéLamos, José Manuel Rodríguez-Vargas, Dik C van Gent |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 98 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |